{"id":"NCT01402492","sponsor":"University of California, Los Angeles","briefTitle":"Cocaine Use Reduction With Buprenorphine","officialTitle":"Cocaine Use Reduction With Buprenorphine (CURB)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-09","primaryCompletion":"2013-01","completion":"2013-03","firstPosted":"2011-07-26","resultsPosted":"2021-10-29","lastUpdate":"2021-10-29"},"enrollment":302,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cocaine Dependence"],"interventions":[{"type":"DRUG","name":"Buprenorphine + Naltrexone","otherNames":["Suboxone","buprenorphine/naloxone","Vivitrol","extended release injectable naltrexone"]},{"type":"DRUG","name":"Placebo + Naltrexone","otherNames":["Vivitrol","extended release injectable naltrexone"]}],"arms":[{"label":"BUP4+XR-NTX","type":"EXPERIMENTAL"},{"label":"BUP16+XR-NTX","type":"EXPERIMENTAL"},{"label":"PLB+XR-NTX","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this study is to investigate the safety and effectiveness of buprenorphine in the presence of naltrexone for the treatment of cocaine dependence.","primaryOutcome":{"measure":"Cocaine Use Days as Measured by Self-report, Corroborated by Thrice-weekly Urine Drug Screens","timeFrame":"final 30 days of Treatment Phase, study days 25-54","effectByArm":[{"arm":"BUP4+XR-NTX","deltaMin":6.6,"sd":5.25},{"arm":"BUP16+XR-NTX","deltaMin":7.2,"sd":6.77},{"arm":"PLB+XR-NTX","deltaMin":7.7,"sd":6.16}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":7},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":["26948856","23159524"],"seeAlso":["http://www.drugabuse.gov/CTN/","http://ctndisseminationlibrary.org/","http://www.uclaisap.org/"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":100},"commonTop":["Nausea","Vomiting","Constipation","Dizziness","Diarrhea"]}}